Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice

INTRODUCTION: Romiplostim has been approved in Europe since 2009 to treat patients with chronic primary immune thrombocytopenia (ITP). Using real-world data from seven European countries, we measured the effectiveness and safety outcomes within 24 weeks following romiplostim initiation by duration o...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Adv Ther
मुख्य लेखकों: Snell Taylor, Sara J., Nielson, Carrie M., Breskin, Alexander, Saul, Bradley, Yu, Ying, Alam, Naufil, Eisen, Melissa, Hippenmeyer, Jane, Janssens, Ann, Kozak, Tomas, Papadaki, Helen A., Selleslag, Dominik, Viallard, Jean-Francois, Feistritzer, Clemens, Kaiafa, Georgia, Kelsh, Michael, Kilpatrick, Karynsa, Brookhart, M. Alan, McGrath, Leah J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer Healthcare 2021
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107157/
https://ncbi.nlm.nih.gov/pubmed/33866516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01727-5
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन